Now that we have identified the role of ADORA2A-AS1 in CML, it is of great significance to understand its potential mechanism for further discovering new CML targets and improving the treatment of CML. Here, ADORA2A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.